A multi-institutional clinical trial has given good results for a targeted therapy to treat a rare, aggressive blood cancer known as blastic plasmacytoid dendritic-cell neoplasm (BPDCN). Details on the trial, which supported Food and Drug Administration approval of the tagraxofusp therapy in December 2018, have been published in the New England Journal of Medicine.
You may also like
Medical News Today: Bubonic plague: Third case reported in China
- November 20, 2019
This week, officials have receivedRead more
Families of youth with autism face big barriers to care, gaps in services
- November 19, 2019
New research at Case Western ReserveRead more